2012
DOI: 10.3109/14756366.2012.672413
|View full text |Cite
|
Sign up to set email alerts
|

Famotidine inhibits glycogen synthase kinase-3β: An investigation by docking simulation and experimental validation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2019
2019
2025
2025

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 13 publications
0
5
0
Order By: Relevance
“…GSK‐3 β crystal structure with PDB: 1Q5 K consists of two chains A and B with the sequence length of 414. The binding pocket was defined from the crystallographic structure of AR‐A014418, which is a known GSK‐3 β ligand with high affinity [66] . The main residues in this pocket were ILE‐62, ALA‐83, ASP‐133, VAL‐135**, ARG‐141 and LEU‐188.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…GSK‐3 β crystal structure with PDB: 1Q5 K consists of two chains A and B with the sequence length of 414. The binding pocket was defined from the crystallographic structure of AR‐A014418, which is a known GSK‐3 β ligand with high affinity [66] . The main residues in this pocket were ILE‐62, ALA‐83, ASP‐133, VAL‐135**, ARG‐141 and LEU‐188.…”
Section: Resultsmentioning
confidence: 99%
“…The binding pocket was defined from the crystallographic structure of AR-A014418, which is a known GSK-3β ligand with high affinity. [66] The main residues in this pocket were ILE-62, ALA-83, ASP-133, VAL-135**, ARG-141 and LEU-188. Molecular docking of triolein, trilinolein, trimyristin, oleic acid, linoleic acid, myristic acid and AR-A014418 inhibitor within the binding pocket of GSK-3β was performed.…”
Section: Molecular Docking Studymentioning
confidence: 97%
“…Despite the different kinase inhibitory properties of the investigated drugs, they have all been shown to have the ability to also inhibit GSK3. This was demonstrated in separate invitro studies [23][24][25][26][27][28]. Famotidine is a competitive inhibitor of the histamine (H2) receptor, the dominant receptor involved in gastric acid secretion that abolishes the activation of adenylate cyclase induced by histamines.…”
Section: Kinase Inhibitory Properties Of Investigated Drugsmentioning
confidence: 91%
“…Famotidine and Olanzapine have been investigated for their potential to inhibit GSK3 due to their hypoglycemic side effects. Docking and experimental studies have demonstrated that Famotidine is fit within the binding pocket of GSK-3β and can decrease the glycemic response curve in animals [23][24][25].…”
Section: Kinase Inhibitory Properties Of Investigated Drugsmentioning
confidence: 99%
See 1 more Smart Citation